Oak Ridge Investments LLC Has $18.41 Million Holdings in Retrophin, Inc. (RTRX)
Oak Ridge Investments LLC trimmed its stake in Retrophin, Inc. (NASDAQ:RTRX) by 27.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 739,462 shares of the biopharmaceutical company’s stock after selling 283,409 shares during the period. Oak Ridge Investments LLC owned about 1.93% of Retrophin worth $18,405,000 as of its most recent SEC filing.
Other large investors also recently made changes to their positions in the company. Nationwide Fund Advisors grew its position in Retrophin by 14.6% in the second quarter. Nationwide Fund Advisors now owns 59,424 shares of the biopharmaceutical company’s stock valued at $1,152,000 after acquiring an additional 7,583 shares during the period. Prudential Financial Inc. bought a new stake in Retrophin in the second quarter valued at $775,000. State of Wisconsin Investment Board acquired a new position in Retrophin in the second quarter worth $543,000. Emory University acquired a new position in Retrophin in the second quarter worth $1,767,000. Finally, Schwab Charles Investment Management Inc. boosted its stake in Retrophin by 35.7% in the second quarter. Schwab Charles Investment Management Inc. now owns 277,688 shares of the biopharmaceutical company’s stock worth $5,385,000 after purchasing an additional 73,067 shares in the last quarter.
A number of equities analysts have commented on RTRX shares. BMO Capital Markets reissued a “buy” rating and issued a $44.00 price objective on shares of Retrophin in a research note on Friday, October 6th. BidaskClub raised Retrophin from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 24th. ValuEngine raised Retrophin from a “sell” rating to a “hold” rating in a research note on Friday, August 4th. Finally, Zacks Investment Research lowered Retrophin from a “hold” rating to a “strong sell” rating in a research note on Tuesday. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $36.00.
COPYRIGHT VIOLATION WARNING: This story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/11/17/oak-ridge-investments-llc-has-18-41-million-holdings-in-retrophin-inc-rtrx.html.
Retrophin, Inc. (RTRX) traded up $0.59 during trading on Friday, reaching $21.68. The company’s stock had a trading volume of 323,200 shares, compared to its average volume of 334,884. The company has a current ratio of 3.88, a quick ratio of 3.83 and a debt-to-equity ratio of 0.15. Retrophin, Inc. has a one year low of $15.55 and a one year high of $26.44.
Retrophin (NASDAQ:RTRX) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.21). Retrophin had a negative return on equity of 10.13% and a negative net margin of 33.79%. The business had revenue of $40.34 million during the quarter, compared to analyst estimates of $40.51 million. During the same period in the prior year, the firm posted ($0.09) EPS. Retrophin’s revenue for the quarter was up 18.8% compared to the same quarter last year. research analysts anticipate that Retrophin, Inc. will post -1.25 earnings per share for the current year.
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Receive News & Stock Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related stocks with our FREE daily email newsletter.